| 1 | Cholecystectomy does not significantly increase the risk of fatty liver disease显示文摘AIM: To investigate the relationship between cholecystectomy and fatty liver disease(FLD) in a Chinese population.METHODS: A total of 32428 subjects who had voluntarily undergone annual health checkups in the Second Affiliated Hospital of Nanjing Medical University from January 2011 to May 2013 were included in this study. Basic data collection, physical examination, laboratory examination, and abdominal ultrasound examination were performed.RESULTS: Subjects undergoing cholecystectomy were associated with greater age, female sex, higher body mass index, and higher levels of systolic blood pressure, diastolic blood pressure, fasting plasma glucose, total cholesterol, and triglycerides. However, no significant differences were found in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, gammaglutamyl transpeptidase, albumin, and serum uric acid. The overall prevalence of FLD diagnosed by ultrasonography was high at 38.4%. The prevalence of FLD was significantly higher for subjects who had undergone cholecystectomy(46.9%) than those who had not undergone cholecystectomy(38.1%; χ2 test, P < 0.001). Cholecystectomy was positively associated with FLD(OR = 1.433, 95%CI: 1.259-1.631). However, after adjusting for possible factors associated withFLD, multivariate regression analysis showed that the association between cholecystectomy and FLD was not statistically significant(OR = 1.096; 95%CI: 0.939-1.279). CONCLUSION: According to our study results, cholecystectomy may not be a significant risk factor for FLD. | Hong-Gang Wang Li-Zhen Wang Hang-Jiang Fu Peng Shen Xiao-Dan Huang Fa-Ming Zhang Rui Xie Xiao-Zhong Yang Guo-Zhong Ji | 2015 | World Journal of Gastroenterology2015，21，12： | 3 |
| 2 | FibroScan-CAP评价水飞蓟宾联合运动疗法治疗非酒精性脂肪性肝炎疗效分析显示文摘目的应用瞬时弹性成像(FibroScan)技术受控衰减参数(CAP)观察水飞蓟宾联合运动疗法治疗非酒精性脂肪性肝炎(NASH)的临床疗效。方法 2013年3月-2014年9月鹤壁市传染病医院门诊及住院的NASH患者65例,均在积极治疗原发病的基础上给以飞蓟宾胶囊,开始每次2粒(70 mg),3次/d口服,4周为1疗程,12周为总疗程。并同时进行运动疗法:由2名接受专业培训的临床医师负责评估,并且个体化定制个人运动计划。每2~4周检测并记录患者临床症状、体质量指数(BMI)、腰围/臀围(ACR)、肝功能、血脂指标的变化以及CAP。结果联合治疗后乏力、纳差、腹胀、肝区隐痛等比例与治疗前比较差异均有统计学意义(P<0.01);治疗后TG、TC、ALT、AST水平及BMI、ACR等较治疗前改善明显,差异有统计学意义(P<0.05或P<0.01);治疗后第8、12周CAP较治疗前差异有统计学意义(P<0.05、P<0.01)。结论飞蓟宾联合运动疗法可以改善NASH患者的临床症状、血清生化指标、BMI及ACR。应用FibroScan-CAP动态检测肝脂肪变是一种无创、定量、快速、可靠的评估脂肪性肝病的新方法。 | 牛卫理 孙亮 杨小军 纪明平 崔小玲 | 2015 | 慢性病学杂志2015，15，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员